%0 Letter
%T [Drug approval: ATEZOLIZUMAB as monotherapy in NSCLC PD-L1 ≥ 50%, without EGFR mutation or ALK rearrangement, for adjuvant treatment after complete surgery and platinum-based chemotherapy].
%A Boudier B
%A Aldea M
%J Bull Cancer
%V 0
%N 0
%D Feb 2023 15
%M 36803981
%F 1.318
%R 10.1016/j.bulcan.2023.01.007
%X